Since the absence of IL-21 signaling prevented islet allograft rejection indicating a robust influence of IL-21 on a graft-mounted immune response, these findings imply that therapeutic manipulation of IL-21 may serve as a suitable treatment for patients with T1D. Here, IL21 is linked to type 1 diabetes mellitus.